CD4 and neoplasm: In Prof. Rosenberg’s clinical study [13] on the identification of tumor neoantigen using reactive tumor-infiltrating lymphocytes from 75 patient gastrointestinal cancers, one patient of MUC4 mutant neoantigen was recognized by CD8+ T cells and another patient with MUC6 mutant neoantigen were recognized by CD4+ T cells.